Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder
NCT06521476
Recruiting
Patients with opioid use disorder treated with either methadone or buprenorphine are at risk of developing central sleep apnea (CSA) from these medications. Investigators will conduct a mechanistic trial using acetazolamide, a medicine known to improve CSA in other settings, to determine if acetazolamide can improve CSA due to medication for opioid use disorder and whether this leads to physiologic changes that might lead to reduced drug craving. Patients treated with medication for opioid use d... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/11/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Central Sleep Apnea Comorbid With Opioid Use
Register for Updates
A Study of Ranolazine in ALS
NCT06527222
Recruiting
The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: University of California, San Francisco, San Francisco, California +6 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
NCT06528301
Recruiting
This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: City of Hope, Duarte, California +7 locations
Conditions: Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia (CLL)
Register for Updates
Using Dichoptic Therapy to Treat Intermittent Exotropia
NCT06529016
Recruiting
Intermittent exotropia is difficult to treat. The mainstay of treatment involves surgery, and in one long-term study authors found that as many as 60% of IXT required at least one re-operation.Patching of the non-dominant eye has also been tested in a large, multi-center randomized control trial and was not found to have a large benefit. More non-surgical treatment modalities are critical to improve the care in this condition.
Gender:
ALL
Ages:
Between 4 years and 7 years
Trial Updated:
07/11/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Exotropia Intermittent
Register for Updates
Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
NCT06538181
Recruiting
VEXAS (vacuoles, E1 ubiqutin-activating enzyme, X-linked, autoinflammatory, somatic syndrome) is a recently described disorder with severe hematologic and rheumatologic manifestations caused by somatic variants in the ubiquitin- activating enzyme gene, UBA1, that is acquired in hematopoietic progenitor cells. Patients are often debilitated by autoinflammatory symptoms and there is currently no standard of care available. There is a clinically unmet need for better therapies in VEXAS Syndrome. Th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome, VEXAS, Vexas Syndrome
Register for Updates
American Indian Smokefree Native RCT
NCT06544811
Recruiting
The aim of this clinical trial is to test the efficacy of a culturally aligned digital smoking cessation resource for American Indian persons who smoke, via a remotely conducted randomized controlled trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Smoking Cessation
Register for Updates
CCHS Secure Health-hub Advancing Research Efforts (CCHS SHARE)
NCT06554275
Recruiting
The purpose of this study is to capture longitudinal natural history data in Congenital Central Hypoventilation Syndrome (CCHS). This will include capturing standardized clinical data from standard of care assessments at several CCHS referral centers. Funding source-FDA OOPD
Gender:
ALL
Ages:
All
Trial Updated:
07/11/2025
Locations: Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Congenital Central Hypoventilation Syndrome
Register for Updates
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
NCT06572228
Recruiting
This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe. Uncontrolled asthma means that patients are still having frequent symptoms while taking their current asthma medication. The aim of the study is to see which regimen is more effective: taking dupilumab with an inhaled asthma medication or only taking a higher dose of the inhaled asthma medicati... Read More
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
07/11/2025
Locations: Kern Research, Inc, Bakersfield, California +79 locations
Conditions: Asthma
Register for Updates
Digital Support for Mental Health Intervention in Patients With Inflammatory Bowel Disease
NCT06575660
Recruiting
This is a small, exploratory study that will investigate using an artificial intelligence (AI) and virtual reality (VR), digital wellness application (app) to deliver a mental health support session in outpatient and hospitalized patients with inflammatory bowel disease (IBD) and co-existing symptoms of mild to moderate anxiety or depression. The purpose of this study is to explore if a mental health support session using the app is feasible, safe, and acceptable to IBD patients and whether it... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Inflammatory Bowel Diseases, Anxiety, Depression, Ulcerative Colitis, Crohn Disease
Register for Updates
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357
Recruiting
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.
Gender:
ALL
Ages:
Between 60 years and 90 years
Trial Updated:
07/11/2025
Locations: JEM Research Institute, Atlantis, Florida +22 locations
Conditions: Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Register for Updates
A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74
NCT06597656
Recruiting
This is a gene transfer therapy study evaluating the safety of and delandistrogene moxeparvovec dystrophin protein expression from delandistrogene moxeparvovec following therapeutic plasma exchange (plasmapheresis) in ambulatory male participants with DMD and pre-existing antibodies to AAVrh74 over a period of 59 weeks.
Gender:
MALE
Ages:
Between 4 years and 8 years
Trial Updated:
07/11/2025
Locations: University of Florida, College of Medicine, Gainesville, Florida +2 locations
Conditions: Duchenne Muscular Dystrophy
Register for Updates
Clinical Study of the inQB8 TTVR System
NCT06611579
Recruiting
Prospective, multi-center study to assess safety and performance of the inQB8 MonarQ Tricuspid Valve Replacement System.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California +4 locations
Conditions: Tricuspid Valve Regurgitation
Register for Updates